Larry comes to TGaS bringing over 20 years of experience in in the pharmaceutical industry, concentrated in commercial operations and analytics. Notably he has deep experience in building out commercial insights and analytics capabilities in the rare disease setting. Larry spent the first decade of his career with Wyeth holding various roles in commercial operations and secondary market research. The last 14 years of his career have been spent with ViroPharma, Shire, Spark, Aurinia and F2G focused on launching first-in-class rare disease and gene therapies. His wealth of knowledge and experience will bring great value to our clients and our own capabilities.